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Abstract
Background: The human leucine-rich, repeat-containing G protein-coupled receptor (LGR) 5, also called GPR49, is a
marker of stem cells in adult intestinal epithelium, stomach and hair follicles. LGR5/GPR49 is overexpressed in
tumors of the colon, ovary and liver and in basal cell carcinomas. Moreover, an expression in skeletal muscle
tissues was also detected. However, there has been no investigation regarding the expression and function of
LGR5/GPR49 in soft-tissue sarcomas (STS) yet.
Methods: Seventy-seven frozen tumor samples from adult STS patients were studied using quantitative real-time
TaqMan™ PCR analysis. The mRNA levels of wild type LGR5/GPR49 and a newly identified splice variant of LGR5/
GPR49 lacking exon 5 (that we called GPR49Δ5) were quantified.
Results: A low mRNA expression level of GPR49Δ5, but not wild type LGR5/GPR49, was significantly correlated with
a poor prognosis for the disease-associated survival of STS patients (RR = 2.6; P = 0.026; multivariate Cox’s
regression hazard analysis). Furthermore, a low mRNA expression level of GPR49Δ5 was associated with a shorter
recurrence-free survival (P = 0.043). However, tumor onset in patients with a lower expression level of GPR49Δ5
mRNA occurred 7.5 years later (P = 0.04) than in patients with a higher tumor level of GPR49Δ5 mRNA.
Conclusion: An attenuated mRNA level of the newly identified transcript variant GPR49Δ5 is a negative prognostic
marker for disease-associated and recurrence-free survival in STS patients. Additionally, a lower GPR49Δ5 mRNA level
is associated with a later age of tumor onset. A putative role of GPR49Δ5 expression in tumorigenesis and tumor
progression of soft tissue sarcomas is suggested.
Background
Treatment options for soft tissue sarcomas (STS) are
often limited to surgery with the possibility of adjuvant
chemotherapy and radiotherapy. The 5-year survival rate
for STS patients is approximately 50% and depends
strongly on the tumor stage [1]. Therefore, it is neces-
sary to develop new prognostic markers with the poten-
tial to estimate the efficacy of an individual therapeutic
strategy.
STS are a heterogeneous group of relatively aggressive
tumors probably originating from adult mesenchymal
stem cells (hMSCs) [2-4]. A study regarding a subgroup
of STS (malignant fibrous histiocytoma; MFH) described
h M S C sa st h ep r o g e n i t o r so fM F H .F u r t h e r m o r e ,t h e
authors reported a novel tumor suppression role for
Wnt signaling in solid tumors, which may have the
potential for a new therapeutic strategy in sarcomas [5].
Here, we investigated the prognostic impact of the
stem cell marker, cancer-associated gene and Wnt/Tcf4
target gene LGR5/GPR49 [6] in STS for the first time.
The leucine-rich repeat-containing G protein-coupled
receptor LGR5/GPR49 has been identified as a novel
stem cell marker in intestinal epithelia, stomach, and
hair follicles [7-9]. Furthermore, LGR5/GPR49 mRNA
was found to be expressed in normal human skeletal
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[10].
LGR5/GPR49 mRNA is expressed in basal cell carci-
noma (tumor of hair follicle), colorectal cancer and in
tumors of the colon, ovary and liver [10-13]. Investiga-
tions of the LGR5/GPR49 protein expression are rare
[14,15] because a full accepted antibody against LGR5/
GPR49 is not available at the moment [6,16]. However,
ap r o g n o s t i ci m p a c to fLGR5/GPR49 has not been
shown so far.
The function of LGR5/GPR49 in tumorigenesis is sup-
ported by its ability to induce transformation of
NIH3T3 cells in the presence of conditioned media
from colorectal tumor cells. These findings indicate the
possibility that the ligand of LGR5/GPR49 could be
secreted by tumor cells [10]. McClanahan and collea-
gues therefore suggest a role for LGR5/GPR49 as a
member of a novel class of transforming oncogenes and,
as a result, a new potential molecular target for thera-
peutic intervention [10].
To our knowledge only one transcript variant of
LGR5/GPR49, which lacks exon 8, is published in the
ExPASy UniProtKB-data bank as variant VSP_037746
http://www.uniprot.org/uniprot/O75473. In this study,
we identified a novel transcript variant of LGR5/GPR49
that lacks exon 5 (GPR49Δ5) (listed by us in the EMBL-
Bank; http://www.ebi.ac.uk/ena/data/view/FN820440).
These variants are very interesting because both pub-
lished LGR5/GPR49 variants have a truncated ligand
binding extracellular domain [6,10]. It is possible that
the affinity of these variants to the recently identified
ligand of the full length LGR5/GPR49 gene product [17]
is different or that different ligands could bind to the
shortened receptor.
In summary, we report the first results for a newly
identified variant of the LGR5/GPR49 gene, lacking exon
5, that we call GPR49Δ5. This is the first study that has
demonstrated a prognostic impact of a LGR5/GPR49
v a r i a n ti nS T S .I nam u l t i v a r i a t eC o x ’s regression analy-
sis, we found that a low GPR49Δ5 mRNA level is an
independent negative prognostic marker for disease-
associated survival as well as for recurrence-free survival
in STS patients.
Methods
Tissue samples and histopathological data
We examined frozen tumor samples from 77 STS
patients using a real-time quantitative TaqMan™ analy-
sis. The patients’ median age was 59 years (ranging from
22 to 87 years). Forty-one patients (53%) died from their
tumor after an average time of 28 months (ranging from
2-119 months), and 36 patients (47%) were still alive
after an average observation period (i.e. after primary
tumor resection) of 65 months (ranging from 11-146
months). The histopathological and clinical data has
been summarized in Table 1 as described previously
[18]. All tumor samples were collected before radio- or
chemotherapy. After the tumor operation 27/77 patients
were treated only with radiotherapy, two out of 77
patients were treated only with chemotherapy, and four
patients were treated with a combination of chemother-
apy and radiotherapy.
The study was carried out in compliance with the Hel-
sinki Declaration, and it was approved by the Ethics
Committee of the Medical Faculty of the University
Halle. All patients gave written informed consent
(Department of Surgery 1, University of Leipzig,
Germany).
Quantitative RT-PCR
Isolation of total RNA and cDNA synthesis were per-
formed according to standard protocols as described
previously [19]. The cDNA was amplified by automated
real-time quantitative TaqMan™ assays for the wild
type LGR5/GPR49 and GPR49Δ5 transcript variants and
Hypoxanthin- guanine -phosphoribosyltransferase
(HPRT) transcript using kits from Roboscreen (AJRo-
boscreen GmbH, Leipzig, Germany).
Wild type LGR5/GPR49 and GPR49Δ5 transcript
amounts were correlated to HPRT transcript amounts as
zeptomole (zmol, 10
-21)w i l dt y p eLGR5/GPR49 or
GPR49Δ5 mRNAs per molecule HPRT mRNA in dupli-
cate measurements.
An elevated expression of wild type LGR5/GPR49 was
determined as an expression of > 1.07 × 10
-5 zmol wild
type LGR5/GPR49 mRNA/molecule HPRT mRNA and
for GPR49Δ5 as an expression of > 7.6 × 10
-6 zmol
GPR49Δ5 mRNA/molecule HPRT mRNA.
Statistical analysis
Cox’s regression hazard models and Kaplan-Meier ana-
lyses were used to estimate a correlation of wild type
LGR5/GPR49 and GPR49Δ5 mRNA with disease-asso-
ciated survival of STS patients. Cox’s regression hazard
model was adjusted to the prognostic effect of covari-
ates (gender of patients, tumor stage, tumor entity,
tumor localization, and type of tumor resection), and
the relative risk (RR) was calculated. For analyzing the
recurrence-free survival of STS patients, a Kaplan-
Meier analysis was performed. The follow-up time
starts with the day of primary tumor operation. The
end point for the disease-associated survival analysis
was the time of death of the patient. The end point for
the recurrence-free survival analysis was the first
recurrence. The interrelationship between gene expres-
sion levels was tested with the Spearman’s rank corre-
lation (r, correlation coefficient). A probability (P) of <
0.05 was defined as significant. Statistical analyses were
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I n c . ,C h i c a g o ,U S A ) .
Results
Correlation of the mRNA expression level with survival of
the STS patients
The median transcript ratios of 77 STS samples were
1.07 × 10
-5 (ranging from 0-4.1 × 10
-3;m e a n2 . 3×1 0
-4)
zmol wild type LGR5/GPR49 mRNA and 7.6 × 10
-6
(ranging from 0-6.4 × 10
-3;m e a n2 . 5×1 0
-4)z m o l
GPR49Δ5 mRNA/molecule HPRT mRNA, respectively.
For the survival analysis, STS patients’ data were sepa-
rated according to the median expression levels. GPR49
low expression was defined as ≤1.07*10
-5 GPR49
mRNA/molecule HPRT mRNA (39 patients) and high
expression was defined as > 1.07*10
-5 GPR49 mRNA/
Table 1 Histopathological and clinical data
Category Patients GPR49-mRNA level
in zmol/molecule HPRT
GPR49Δ5-mRNA level in zmol/molecule HPRT
≤1.07*10
-5 > 1.07*10
-5 ≤7.6*10
-6 > 7.6*10
-6
Total 77 39 38 39 38
P = 0.429 P = 0.212
Men 35 16 19 15 20
Women 42 23 19 24 18
Tumor stage P = 0.023* P = 0.005*
I1 0 1 9 0 1 0
II 33 21 12 21 12
III 26 12 14 13 13
IV 8 5 3 5 3
Tumor type P = 0.194 P = 0.166
liposarcoma 19 6 13 5 14
fibrosarcoma/malignant fibrous histiocytoma 20 9 11 11 9
neurogenic sarcoma 6 3 3 3 3
rhabdomyosarcoma/leiomyosarcoma 22 15 7 14 8
Other STS 10 6 4 6 4
Tumor resection P = 0.377 P = 0.172
radical (R0) 51 24 27 23 28
not radical (R1) 26 15 11 16 10
Patients at follow-up
alive 36 15 21 13 23
dead 41 24 17 26 15
Localization P = 0.444 P = 0.207
extremities 49 25 24 26 23
thorax 6 2 4 1 5
head 1 0 1 0 1
abdomen 19 10 9 10 9
multiple 2 2 0 2 0
Metastasis P = 0.291 P = 0.025*
M0 21 9 12 7 14
M1 29 17 12 19 10
Age of tumor onset P = 0.218 P = 0.039*
age (mean) 59.9 55.4 61.4 53.9
Kaplan-Meier analysis P = 0.056 P = 0.004*
mean survival (months) 50.1 ± 6.5 80.3 ± 10.7 45.8 ± 6.4 86.2 ± 10.9
Univariate Cox’s Regression P = 0.06 P = 0.006*
RR 1.8 2.5
CI 0.97-3.5 1.3-4.8
Multiv. Cox’s-Regression P = 0.12 P = 0.026*
RR 1.8 2.6
CI 0.9-4.0 1.1-6.0
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expression was defined as ≤7.6*10
-6 GPR49Δ5m R N A /
molecule HPRT mRNA (39 patients and high expression
was defined as > 7.6*10
-6 GPR49Δ5m R N A / m o l e c u l e
HPRT) (38 patients). The separation was based on the
median expression level of the wild type LGR5/GPR49
mRNA and GPR49Δ5 mRNA (see also Table 1).
We performed a Kaplan-Meier analysis, which detected
that STS patients with a lower intratumoral expression of
wild type LGR5/GPR49 mRNA died an average of 30
months earlier (P = 0.056), with lower intratumoral
GPR49Δ5 mRNA expression died an average of 40
months earlier (P = 0.004) than patients who had higher
intratumoral expression of wild type LGR5/GPR49
mRNA and GPR49Δ5 mRNA, respectively (Table 1).
Multivariate Cox’s regression hazard analysis revealed an
increased risk (RR = 1.8, P = 0.12, Table 1) of tumor-
related death for patients with a low wild type LGR5/
GPR49 mRNA level and a 2.6-fold (P = 0.026) increased
risk for STS patients with a low level of GPR49Δ5 mRNA
in their tumors, respectively (Figure 1).
Moreover, when we estimated recurrence-free survival,
al o wl e v e lo fGPR49Δ5 mRNA expression was signifi-
cantly associated with an early recurrence (P = 0.043;
Figure 2), whereas low wild type LGR5/GPR49 mRNA
expression levels had no significant effect (P = 0.20).
Furthermore, we found a significant difference in
tumor onset (7.5 yrs) between STS patients with a low
level compared to patients with a high level of GPR49Δ5
mRNA expression (61.4 vs. 53.9 yrs) in their tumors (P
= 0.039; Student’s t-test, Table 1; Figure 3).
Correlation with clinical parameters
Bivariate analysis demonstrated that low expression of
wild type LGR5/GPR49 mRNA correlated with higher
tumor stage (P = 0.02). Low expression of GPR49Δ5
mRNA was also significantly associated with higher
tumor stage (P = 0.005) and, moreover, with the occur-
rence of late distant metastases (P = 0.025) (Table 1).
The mean intratumoral expression of GPR49Δ5 mRNA
in the primary tumor was a 6fold lesser (6.9 × 10
-5 vs. 4.3
×1 0
-4 zmol GPR49Δ5 mRNA/molecule HPRT mRNA)
for those patients (n = 29) who developed metastases
compared to patients (n = 21) without metastases.
Discussion
In this study, we demonstrated that a low GPR49Δ5
mRNA level is a negative prognostic marker for disease-
Figure 1 Multivariate Cox’s hazard regression model for GPR49Δ5 mRNA expression level and disease-associated survival in STS
patients. Expression level of GPR49Δ5 mRNA in STS of 77 patients was correlated with disease-associated survival. The model was adjusted to
patients’ gender, tumor stage, tumor localization, tumor entity, and the type of tumor resection. The high and low cut-off values for GPR49Δ5
were > 7.6 × 10
-5 and ≤7.6 × 10
-5 zmol GPR49Δ5 mRNA/molecule HPRT mRNA (RR = 2.6, P = 0.026).
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(Table 1).
LGR5/GPR49 labels stem cells in intestines, stomach
and hair follicles [7-9]. When compared to correspond-
ing normal tissues, LGR5/GPR49 mRNA is overex-
pressed in human hepatocellular carcinomas, basal cell
carcinoma, colon-, colorectal- and ovarian tumors
[10-13,20]. However, Yamamoto et al.f o u n dn os i g n i f i -
cant association between expression of LGR5/GPR49
and clinicopathologic features of tumors [12]. We found
that low mRNA expression of GPR49Δ5 has a prognos-
tic impact for STS patients.
Why does low expression impact survival? We found
that low expression of wild type LGR5/GPR49 mRNA (P
= 0.023), as well as low expression of GPR49Δ5 mRNA
(P = 0.005), was significantly associated with a higher
tumor stage. STS patients with high-stage tumors have a
poorer prognosis than those with low-stage tumors [21].
In accordance with our results, McClanahan and collea-
gues observed that in both colorectal and ovarian carci-
nomas expression of LGR5/GPR49 mRNA was high in
stage I and II tumors and appears to decrease in stage III
and IV tumors. The authors suggest that overexpression
of LGR5/GPR49 may be an early event in tumorigenesis
[10]. Furthermore, using a mouse endometrial cancer
model, Sun et al.f o u n dt h a tLGR5/GPR49 mRNA is
highly expressed in the epithelium during the initial
stages of tumorigenesis, but is remarkably down-regu-
lated in full-grown tumors [22]. Fan et al. postulated a
function for LGR5/GPR49 in the initiation of colorectal
carcinomas [14]. This hypothesis corresponds with our
finding that patients with lower-staged tumors had
higher GPR49Δ5 mRNA levels, but earlier tumor onset.
However, low expression of GPR49Δ5 mRNA appears
to be associated with tumor progression. Low expression
of GPR49Δ5 mRNA is correlated with poor recurrence-
free survival (P = 0.043) in STS patients and with the
occurrence of late distant metastases (P = 0.025). Uchida
et al. described diffuse LGR5/GPR49 mRNA expression
in the entire tumor, as well as in the invasive front of
human colorectal carcinomas [20]. LGR5/GPR49 mRNA
expression in colorectal carcinomas correlated signifi-
cantly with the number of lymph node metastases, lym-
phatic invasion, and vascular invasion [20]. Moreover,
the expression of LGR5/GPR49 mRNA was significantly
associated with poor prognosis for disease-free survival
of colorectal cancer patients [11]. These data suggest,
that LGR5/GPR49 mRNA expression may be associated
Figure 2 Kaplan-Meier analysis recurrence-free survival curves according to GPR49Δ5 transcript levels. Expression of GPR49Δ5 mRNA for
77 patients with STS was correlated with recurrence-free survival. The high and low cut-off values for GPR49Δ5 were > 7.6 × 10
-5 and ≤7.6 × 10
-5
zmol GPR49Δ5 mRNA/molecule HPRT mRNA (P = 0.043).
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including the appearance of metastasis [20].
Recently and in accordance to our results, Walker and
colleagues described that an ablation of LGR5 induces
increased invasion and anchorage-independent growth,
and enhances tumourigenicity in xenografts experiments
of human colorectal cancers. Suppression of LGR5/
GPR49 leads to a strong upregulation of mesenchymal
genes and of genes positively regulating EMT (Epithelial
to Mesenchymal Transition) - the same genes are mark-
edly downregulated upon LGR5 overexpression [23].
These findings suggest that LGR5/GPR49 is important
in restricting stem cells to their niche, and that loss of
LGR5 concomitant with activated wnt signalling may
contribute to the invasive phenotype of colorectal carci-
nomas. These results highlight the importance of LGR5,
not simply as marker of colorectal tumor cells, but as a
regulator of wnt responses, cell motility and cell-cell
adhesion [23].
This fact can be of importance even for tumors of
mesenchymal origin like STS.
Conclusion
In this study, we analyzed mRNA expression of an addi-
tional stem cell-associated gene, LGR5/GPR49 and its
splice variant GPR49Δ5, for its association with disease-
associated and recurrence-free survival. We were able to
identify GPR49Δ5 mRNA expression as an independent
prognostic factor for STS patients. We suggest that
stem-cell-associated genes play a major role in sarcoma
patients’ prognosis and, therefore, could be valuable tar-
gets for future therapy. Together, our results suggest a
role of GPR49Δ5 in tumorigenesis and tumor progres-
sion of STS.
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